Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
Moorman AV, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, Gibson B, Goulden N, Kearns P, James B, Kirkwood AA, Lancaster D, Madi M, McMillan A, Motwani J, Norton A, O'Marcaigh A, Patrick K, Bhatnagar N, Qureshi A, Richardson D, Stokley S, Taylor G, van Delft FW, Moppett J, Harrison CJ, Samarasinghe S, Vora A.
Moorman AV, et al. Among authors: moppett j.
Br J Haematol. 2020 Dec;191(5):844-851. doi: 10.1111/bjh.17093. Epub 2020 Sep 14.
Br J Haematol. 2020.
PMID: 32926422
Free article.
Clinical Trial.